ATE408622T1 - Urocortinproteine und deren verwendungen - Google Patents

Urocortinproteine und deren verwendungen

Info

Publication number
ATE408622T1
ATE408622T1 AT01963759T AT01963759T ATE408622T1 AT E408622 T1 ATE408622 T1 AT E408622T1 AT 01963759 T AT01963759 T AT 01963759T AT 01963759 T AT01963759 T AT 01963759T AT E408622 T1 ATE408622 T1 AT E408622T1
Authority
AT
Austria
Prior art keywords
ucn
crf
urp
urocortin
human
Prior art date
Application number
AT01963759T
Other languages
German (de)
English (en)
Inventor
Wylie Vale
Paul Sawchenko
Kathy Lewis
Joan Vaughan
Teresa Reyes
Jean Rivier
John Hogenesch
Marilyn Perrin
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Application granted granted Critical
Publication of ATE408622T1 publication Critical patent/ATE408622T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
AT01963759T 2000-08-04 2001-07-31 Urocortinproteine und deren verwendungen ATE408622T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22325500P 2000-08-04 2000-08-04
US27396901P 2001-03-07 2001-03-07

Publications (1)

Publication Number Publication Date
ATE408622T1 true ATE408622T1 (de) 2008-10-15

Family

ID=26917597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01963759T ATE408622T1 (de) 2000-08-04 2001-07-31 Urocortinproteine und deren verwendungen

Country Status (16)

Country Link
US (4) US6838274B2 (enExample)
EP (1) EP1305334B1 (enExample)
JP (1) JP4873825B2 (enExample)
KR (1) KR100879232B1 (enExample)
CN (1) CN1484650B (enExample)
AT (1) ATE408622T1 (enExample)
AU (2) AU2001284683B2 (enExample)
CA (1) CA2418144C (enExample)
CY (1) CY1110424T1 (enExample)
DE (1) DE60135850D1 (enExample)
DK (1) DK1305334T3 (enExample)
ES (1) ES2313978T3 (enExample)
IL (2) IL154102A0 (enExample)
PT (1) PT1305334E (enExample)
RU (1) RU2278871C2 (enExample)
WO (1) WO2002012307A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154102A0 (en) * 2000-08-04 2003-07-31 Res Dev Foundation Urocortin proteins and uses thereof
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
AU2002306853B2 (en) 2001-03-15 2006-07-06 Research Development Foundation Urocortin-III and uses thereof
US7192923B2 (en) 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
EP2522351B1 (en) 2007-06-13 2017-09-06 Research Development Foundation Treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling
EP2187924A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
WO2009033807A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
WO2011025905A1 (en) 2009-08-28 2011-03-03 Research Development Foundation Urocortin 2 analogs and uses thereof
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
KR102107482B1 (ko) 2012-02-14 2020-05-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 심혈관 질환 및 다른 증상에 대한 파라크린 유전자의 전신 전달 및 조절 발현
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2020176807A1 (en) 2019-02-27 2020-09-03 Vanderbilt University Methods of treating trigeminal nerve pain
CN110826145B (zh) * 2019-09-09 2020-08-28 西安工业大学 基于超启发式马氏链进化的汽车多参数运行工况设计方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223792A1 (en) 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
IL154102A0 (en) * 2000-08-04 2003-07-31 Res Dev Foundation Urocortin proteins and uses thereof
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Also Published As

Publication number Publication date
CN1484650A (zh) 2004-03-24
US7223846B2 (en) 2007-05-29
KR20030074589A (ko) 2003-09-19
CA2418144C (en) 2013-06-18
CY1110424T1 (el) 2015-04-29
EP1305334A1 (en) 2003-05-02
IL154102A (en) 2010-12-30
US7638607B2 (en) 2009-12-29
US20020127221A1 (en) 2002-09-12
US8044025B2 (en) 2011-10-25
PT1305334E (pt) 2008-12-30
US20070191592A1 (en) 2007-08-16
US6838274B2 (en) 2005-01-04
AU2001284683B2 (en) 2006-04-27
DK1305334T3 (da) 2009-02-02
JP4873825B2 (ja) 2012-02-08
CN1484650B (zh) 2012-12-12
DE60135850D1 (de) 2008-10-30
RU2003105897A (ru) 2005-01-20
US20050191650A1 (en) 2005-09-01
ES2313978T3 (es) 2009-03-16
EP1305334B1 (en) 2008-09-17
CA2418144A1 (en) 2002-02-14
EP1305334A4 (en) 2005-03-23
KR100879232B1 (ko) 2009-01-20
IL154102A0 (en) 2003-07-31
AU8468301A (en) 2002-02-18
WO2002012307A1 (en) 2002-02-14
RU2278871C2 (ru) 2006-06-27
US20100168021A1 (en) 2010-07-01
JP2004505640A (ja) 2004-02-26

Similar Documents

Publication Publication Date Title
CY1110424T1 (el) Πρωτεϊνες ουροκορτινης και χρησεις αυτων
Szabo et al. The bovine insulin-like growth factor (IGF) binding protein purified from conditioned medium requires the N-terminal tripeptide in IGF-1 for binding
Zhao et al. The purification and partial amino acid sequence of a polypeptide from the glutelin fraction of rice grains; homology to pea legumin
Böhlen et al. Human brain fibroblast growth factor: Isolation and partial chemical characterization
Okamoto et al. Total chemical synthesis and biological activities of glycosylated and non‐glycosylated forms of the chemokines CCL1 and Ser‐CCL1
EP3428182A2 (en) Anti-inflammatory peptides and composition comprising the same
IE74956B1 (en) Chimeric fibroblast growth factors
Graham et al. Complete amino acid sequence of soybean leaf P21: similarity to the thaumatin-like polypeptides
Crabb et al. Characterization of multiple forms of prostatropin (prostate epithelial cell growth factor) from bovine brain
HU215434B (hu) Eljárás interleukin-1 inhibitorok, ezeket kódoló DNS-szekvenciák, vektorok és gazdasejtek előállítására
Schmelzer et al. Biochemical characterization of recombinant human nerve growth factor
Browning et al. Disulfide scrambling of interleukin-2: HPLC resolution of the three possible isomers
ATE455792T1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
Lund et al. The human chromosomal protein HMG I contains two identical palindrome amino acid sequences
Higuchi et al. The single proline‐glutamine substitution at position 5 enhances the potency of amyloid fibril formation of murine apo A‐II
Leszyk et al. Amino acid sequence of a 15 kilodalton actin-binding fragment of turkey gizzard caldesmon: Similarity with dystrophin, tropomysin and the tropomyosin-binding region of troponin T
Araki et al. The position of the disulfide bonds in human plasma α2HS-glycoprotein and the repeating double disulfide bonds in the domain structure
ATE287952T1 (de) Humanes thymosin beta 15 gen,protein und dessen verwendungen
Harper et al. Human class 1 heparin-binding growth factor: structure and homology to bovine acidic brain fibroblast growth factor
ATE294816T1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
Lundwall et al. Chemical characterization of cyanogen bromide fragments from the β‐chain of human complement factor C3
Feeney et al. Synthesis, expression and characterisation of peptides comprised of perfect repeat motifs based on a wheat seed storage protein
Boumaiza et al. Expression and purification of a new recombinant camel hepcidin able to promote the degradation of the iron exporter ferroportin1
Uegaki et al. Characterization of the DNA binding domain of the mouse IRF-2 protein
Zhang et al. Oxidative folding of hepcidin at acidic pH

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1305334

Country of ref document: EP